NasdaqGS:JAZZPharmaceuticals
Jazz Pharmaceuticals (JAZZ): Valuation Check After Positive Ziihera and Epidiolex Clinical Updates Boost Investor Interest
Jazz Pharmaceuticals (JAZZ) has slipped onto more investors radar after a run of encouraging clinical updates, from fresh Epidiolex seizure data to promising Ziihera results in HER2 positive gastroesophageal cancer and upcoming conference showcases.
See our latest analysis for Jazz Pharmaceuticals.
Those updates seem to be resonating with investors, with the share price now at $167.50 and a strong 30 day share price return of 18.74 percent feeding into a 36.13 percent 1 year total shareholder...